Equities

RPG Life Sciences Limited

RPGLIFE:NSI

RPG Life Sciences Limited

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,991.95
  • Today's Change-40.05 / -1.97%
  • Shares traded28.75k
  • 1 Year change+36.14%
  • Beta1.0704
Data delayed at least 15 minutes, as of Nov 22 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year RPG Life Sciences Limited grew revenues 13.50% from 5.13bn to 5.82bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 29.60% net income growth from 676.40m to 876.60m.
Gross margin67.85%
Net profit margin11.43%
Operating margin15.70%
Return on assets13.92%
Return on equity19.76%
Return on investment19.35%
More ▼

Cash flow in INRView more

In 2024, cash reserves at RPG Life Sciences Limited fell by 51.00m. However, the company earned 943.60m from its operations for a Cash Flow Margin of 16.21%. In addition the company used 791.50m on investing activities and also paid 203.10m in financing cash flows.
Cash flow per share54.35
Price/Cash flow per share37.39
Book value per share229.38
Tangible book value per share213.84
More ▼

Balance sheet in INRView more

RPG Life Sciences Limited uses little or no debt in its capital structure.
Current ratio2.04
Quick ratio1.45
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 29.60%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
Div yield(5 year avg)1.46%
Div growth rate (5 year)46.14%
Payout ratio (TTM)37.45%
EPS growth(5 years)51.98
EPS (TTM) vs
TTM 1 year ago
-8.74
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.